113 related articles for article (PubMed ID: 20735399)
21. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
22. Decreased cyclooxygenase-2 associated with impaired megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia.
Zhuang X; Xu P; Ou Y; Shao X; Li Y; Ma Y; Qin S; Hua F; Zhan Y; Ji L; Qiao T; Chen H; Cheng Y
J Transl Med; 2023 Aug; 21(1):540. PubMed ID: 37573325
[TBL] [Abstract][Full Text] [Related]
23. Thrombocytopenia associated with the induction of neonatal tolerance to alloantigens: immunopathogenic mechanisms.
Merino J; Qin HY; Schurmans S; Gretener D; Grau GE; Lambert PH
Eur J Immunol; 1989 Sep; 19(9):1693-9. PubMed ID: 2792184
[TBL] [Abstract][Full Text] [Related]
24. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction.
Katsman Y; Foo AH; Leontyev D; Branch DR
Transfusion; 2010 Jun; 50(6):1285-94. PubMed ID: 20088841
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock.
MartÃnez C; Juarranz Y; Abad C; Arranz A; Miguel BG; Rosignoli F; Leceta J; Gomariz RP
J Leukoc Biol; 2005 May; 77(5):729-38. PubMed ID: 15661828
[TBL] [Abstract][Full Text] [Related]
26. Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice.
Barbieri SS; Petrucci G; Tarantino E; Amadio P; Rocca B; Pesce M; Machlus KR; Ranelletti FO; Gianellini S; Weksler B; Italiano JE; Tremoli E
Thromb Haemost; 2015 Nov; 114(6):1218-29. PubMed ID: 26272103
[TBL] [Abstract][Full Text] [Related]
27. Neuraminidase-induced thrombocytopenia in mice: effects on thrombopoiesis.
Stenberg PE; Levin J; Baker G; Mok Y; Corash L
J Cell Physiol; 1991 Apr; 147(1):7-16. PubMed ID: 2037624
[TBL] [Abstract][Full Text] [Related]
28. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
29. The neuropeptide pituitary adenylate cyclase activating protein is a physiological activator of human monocytes.
El Zein N; Corazza F; Sariban E
Cell Signal; 2006 Feb; 18(2):162-73. PubMed ID: 15993038
[TBL] [Abstract][Full Text] [Related]
30. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
31. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.
Burian B; Storka A; Marzluf BA; Yen YC; Lambers C; Robibaro B; Vonbank K; Mosgoeller W; Petkov V
Peptides; 2010 Apr; 31(4):603-8. PubMed ID: 20026142
[TBL] [Abstract][Full Text] [Related]
33. The relationship between megakaryocyte ploidy and platelet volume in normal and thrombocytopenic C3H mice.
Corash L; Levin J
Exp Hematol; 1990 Oct; 18(9):985-9. PubMed ID: 2397753
[TBL] [Abstract][Full Text] [Related]
34. Localization of megakaryocytes in normal mice and following administration of platelet antiserum, 5-fluorouracil, or radiostrontium: evidence for the site of platelet production.
Davis RE; Stenberg PE; Levin J; Beckstead JH
Exp Hematol; 1997 Jul; 25(7):638-48. PubMed ID: 9216740
[TBL] [Abstract][Full Text] [Related]
35. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
[TBL] [Abstract][Full Text] [Related]
36. Sustained thrombocytopenia in mice: serial studies of megakaryocytes and platelets.
Stenberg PE; Levin J; Corash L
Exp Hematol; 1990 Feb; 18(2):124-32. PubMed ID: 2303104
[TBL] [Abstract][Full Text] [Related]
37. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
38. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.
Delgado M
Biochem Biophys Res Commun; 2002 May; 293(2):771-6. PubMed ID: 12054537
[TBL] [Abstract][Full Text] [Related]
39. Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP).
Taupenot L; Mahata SK; Wu H; O'Connor DT
J Clin Invest; 1998 Feb; 101(4):863-76. PubMed ID: 9466982
[TBL] [Abstract][Full Text] [Related]
40. Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development.
Basille M; Vaudry D; Coulouarn Y; Jegou S; Lihrmann I; Fournier A; Vaudry H; Gonzalez B
J Comp Neurol; 2000 Oct; 425(4):495-509. PubMed ID: 10975876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
